Predictors of Progression-Free Survival and Local Tumor Control after Percutaneous Thermal Ablation of Oligometastatic Breast Cancer: Retrospective Study

To describe ablation of bone, liver, lung, and soft tissue tumors from oligometastatic breast cancer and to define predictors of local progression and progression-free survival (PFS). A total of 33 women (mean age 52 ± 12 years old; range, 28-69 years), underwent 46 thermal ablations of liver (n = 3...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Journal of vascular and interventional radiology Ročník 31; číslo 8; s. 1201
Hlavní autori:	Ridouani, Fourat, Solomon, Stephen B, Bryce, Yolanda, Bromberg, Jacqueline F, Sofocleous, Constantinos T, Deipolyi, Amy R
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States 01.08.2020
Predmet:	Adult Aged Bone Neoplasms - diagnostic imaging Bone Neoplasms - mortality Bone Neoplasms - secondary Bone Neoplasms - surgery Breast Neoplasms - mortality Breast Neoplasms - pathology Cryosurgery - adverse effects Cryosurgery - mortality Databases, Factual Disease Progression Feasibility Studies Female Humans Liver Neoplasms - diagnostic imaging Liver Neoplasms - mortality Liver Neoplasms - secondary Liver Neoplasms - surgery Lung Neoplasms - diagnostic imaging Lung Neoplasms - mortality Lung Neoplasms - secondary Lung Neoplasms - surgery Margins of Excision Metastasectomy - adverse effects Metastasectomy - methods Metastasectomy - mortality Middle Aged Progression-Free Survival Radiofrequency Ablation - adverse effects Radiofrequency Ablation - mortality Retrospective Studies Risk Factors Soft Tissue Neoplasms - diagnostic imaging Soft Tissue Neoplasms - mortality Soft Tissue Neoplasms - secondary Soft Tissue Neoplasms - surgery Time Factors Tumor Burden
ISSN:	1535-7732, 1535-7732
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Popis
Shrnutí:	To describe ablation of bone, liver, lung, and soft tissue tumors from oligometastatic breast cancer and to define predictors of local progression and progression-free survival (PFS). A total of 33 women (mean age 52 ± 12 years old; range, 28-69 years), underwent 46 thermal ablations of liver (n = 35), lung (n = 7), and bone/soft tissue (n = 4) metastases. Mean tumor diameter was 18 ± 15 mm (range, 6-50 mm). Ablations were performed to eradicate all evident sites of disease (n = 24) or to control growing sites in the setting of other stable or responding sites of disease (n = 22). Patient characteristics, ablation margins, imaging responses, and cases of PFS were assessed. Follow-up imaging was performed using contrast-enhanced computed tomography (CT), magnetic resonance (MR) imaging, or positron-emission tomography/ CT. Median PFS was 10 months (95% confidence interval [CI], 6.2 -14.5 months), and time to local progression was 11 months (95% CI, 5-16 months). Eight patients (24%) maintained no evidence of disease during a median follow-up period of 39 months. Ablation margin ≥5 mm was associated with no local tumor progression. Longer PFS was noted in estrogen receptor-positive patients (12 vs 4 months; P = .037) and younger patients (12 vs 4 months; P = .039) treated to eradicate all sites of disease (13 vs 5 months; P = .05). Eighteen patients (55%) developed new metastases during study follow-up. Thermal ablation of oligometastatic pulmonary, hepatic, bone, and soft tissue tumors can eliminate local tumor progression if margins are ≥5 mm. Longer PFS was observed in patients who were estrogen receptor-positive and patients who were younger and in whom all sites of disease were eradicated.
Bibliografia:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	1535-7732 1535-7732
DOI:	10.1016/j.jvir.2020.02.016